AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24701585
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with propofol (Group T)
Trial: 22240407
Drug: Azithromycin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (30 mg/kg oral dose)
Trial: 22240407
Drug: Benzathine benzylpenicillin
RxNorm normalized name: Benzathine benzylpenicillin
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Benzathine benzylpenicillin (50,000 units/kg intramuscular injection)
Trial: 17959952
Drug: Esmolol (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (continuous infusion of 5-15 microg x kg(‐1) x min(‐1))
Trial: 17959952
Drug: Control (intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (intermittent doses of fentanyl)
Trial: 17959952
Drug: Remifentanil (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (continuous infusion of 0.1-0.5 microg x kg(‐1) x min(‐1))
Trial: 17959952
Drug: Esmolol (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (continuous infusion)
Trial: 10338454
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin treatment
Trial: 3551432
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin treatment
Trial: 14727969
Drug: Early invasive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early invasive strategy combined with early use of tirofiban and standard medical therapy
Trial: 9521971
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (0.5 g topically 1 hour before circumcision)
Trial: 7619356
Drug: 7.5 mg/day
RxNorm normalized name: nicotine 7.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/day moexipril
Trial: 7619356
Drug: 180 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg/day verapamil-SR
Trial: 22858124
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day lutein
Trial: 22858124
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day lutein
Trial: 22858124
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day lutein plus 10 mg/day zeaxanthin
Trial: 8762730
Drug: dexfenfluramine (d-FF)
RxNorm normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexfenfluramine (d-FF) 15 mg twice daily for 6 days
Trial: 30323234
Drug: New administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New administration route (NEW.AR) of alprostadil cream
Trial: 30323234
Drug: Standard administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard administration route (ST.AR) of alprostadil cream
Trial: 29467437
Drug: Accelerated rTMS
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated rTMS (n = 58): 63,000 high frequency rTMS pulses delivered as 3 treatments per day over 3 days in week 1, 3 treatments over 2 days in week 2 and 3 treatments on a single day in week 3
Trial: 27414655
Drug: CYD‐TDV (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYD‐TDV (recombinant live attenuated tetravalent dengue vaccine)
Trial: 22846190
Drug: Vacuum interferential
RxNorm normalized name: thymol
DrugBank: Thymol (DB02513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vacuum interferential current (IFC) therapy, 12 sessions over 4 weeks.
Trial: 22846190
Drug: Placebo therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy, 12 sessions over 4 weeks.
Trial: 20171127
Drug: Benzodiazepine hypnotics
RxNorm normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine hypnotics and Z-drugs (e.g., zolpidem, zopiclone, zaleplon)
Trial: 20171127
Drug: Benzodiazepine hypnotics
RxNorm normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine hypnotics and Z-drugs
Trial: 20171127
Drug: Benzodiazepine hypnotics
RxNorm normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine hypnotics and Z-drugs with alcohol co-administration
Trial: 20171127
Drug: Repeated daily
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated daily use of hypnotic drugs
Trial: 19112511
Drug: Oral Polio
RxNorm normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Polio Vaccine (OPV) at birth
Trial: 15853109
Drug: Optibond dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optibond dual cure (OPTB) with light-curing (LC) and combination of light and chemical curing (LCC)
Trial: 15853109
Drug: Light-curing (LC)
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light-curing (LC) and combination of light and chemical curing (LCC)
Trial: 9060198
Drug: No-additional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-additional treatment control group
Trial: 8457152
Drug: Intraoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative radiotherapy (20-Gy) + postoperative low-dose external-beam radiotherapy (35- to 40-Gy)
Trial: 8457152
Drug: Postoperative high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative high-dose external-beam radiotherapy (50- to 55-Gy) alone (Control)
Trial: 3636335
Drug: Timentin in
RxNorm normalized name: Timentin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timentin in combination with amikacin
Trial: 26073872
Drug: Dexmecamylamine 2
RxNorm normalized name: Dexmecamylamine
DrugBank: Dexmecamylamine (DB11807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmecamylamine 2 mg
Trial: 26073872
Drug: Dexmecamylamine 1
RxNorm normalized name: Dexmecamylamine
DrugBank: Dexmecamylamine (DB11807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmecamylamine 1 mg
Trial: 18326731
Drug: Indomethacin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.4 mg/kg bolus followed by 0.4 mg/kg/h continuous infusion for 120 minutes)
Trial: 16782912
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg by mouth twice daily)
Trial: 12932066
Drug: Unilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral spinal anaesthesia with hyperbaric bupivacaine 7.5 mg 0.5% (Group Spinal)
Trial: 11119192
Drug: Propofol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (12 mg.kg(‐1).h(‐1)) and alfentanil (0.04 mg.kg(‐1).h(‐1))
Trial: 11119192
Drug: Ketamine racemate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine racemate (10-12 mg.kg(‐1).h(‐1)) and midazolam (0.3-0.6 mg.kg(‐1).h(‐1))
Trial: 8241695
Drug: Ubiquinone (coenzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinone (coenzyme Q10), 100 mg/day for 7 months
Trial: 29212528
Drug: Conventional occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occupational and physical therapy
Trial: 19880138
Drug: Hydroxyurea (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (not specified dosage or duration)
Trial: 17696962
Drug: High-dose esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose esomeprazole (40 mg b.d.)
Trial: 17696962
Drug: Low-dose esomeprazole
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose esomeprazole (40 mg o.d.)
Trial: 11930093
Drug: Intensive Medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Medical Therapy (IMT)
Trial: 2565728
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg WY-45,727
Trial: 2565728
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg WY-45,727
Trial: 2565728
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg WY-45,727
Trial: 28188086
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group A (150 mg oral vismodegib per day for 12 weeks, then three rounds of 8 weeks of placebo daily followed by 12 weeks of 150 mg vismodegib daily)
Trial: 28188086
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group B (150 mg oral vismodegib per day for 24 weeks, then three rounds of 8 weeks of placebo daily followed by 8 weeks of 150 mg vismodegib daily)
Trial: 28188086
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group A
Trial: 28188086
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group B
Trial: 25068884
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum (COL; 1.7 g·kg(‐1)·day(‐1) for 7 days)
Trial: 15510897
Drug: Alprazolam 3
RxNorm normalized name: alprazolam 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 3 x 0.5 mg
Trial: 15510897
Drug: Diazepam 3
RxNorm normalized name: diazepam 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 3 x 2 mg
Trial: 11479694
Drug: Cyfra 21-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyfra 21-1 levels after treatment in NSCLC patients
Trial: 8303945
Drug: Lederle/Takeda acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lederle/Takeda acellular pertussis component diphtheria‐tetanus‐pertussis vaccine (APDT)
Trial: 8303945
Drug: Lederle whole‐cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lederle whole‐cell pertussis component diphtheria‐tetanus‐pertussis vaccine (DTP)
Trial: 2498507
Drug: Intralesional recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional recombinant tumor necrosis factor-alpha (rTNF) at a recommended dose of 25 micrograms/m2
Trial: 30296436
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (controls, n = 206)
Trial: 27761981
Drug: Dialysate bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate bicarbonate of 34 mmol/L
Trial: 27761981
Drug: Dialysate bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate bicarbonate of 30 mmol/L
Trial: 24456438
Drug: Prophylactic single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic single-dose antibiotics
Trial: 24456438
Drug: Prolonged course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged course of antibiotics
Trial: 22108776
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) during tuberculosis treatment
Trial: 22108776
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) off tuberculosis treatment
Trial: 22108776
Drug: Slow metabolizers
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow metabolizers with tuberculosis treatment
Trial: 22108776
Drug: Slow metabolizers
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow metabolizers without tuberculosis treatment
Trial: 22108776
Drug: Overall effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall effect of tuberculosis treatment on EFV clearance
Trial: 1911021
Drug: 0.08% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.08% bupivacaine 8 ml
Trial: 1911021
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline 8 ml
Trial: 6811766
Drug: Megavoltage radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megavoltage radiation therapy
Trial: 31587995
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg escitalopram/day in addition to structured psychosocial intervention (PSI)
Trial: 19846844
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg of nonadjuvanted vaccine
Trial: 19846844
Drug: 30 microg
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microg of vaccine (with or without adjuvant)
Trial: 19846844
Drug: Vaccine without
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine without adjuvant
Trial: 16907966
Drug: Isoflavone-enriched cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone-enriched cereal bars (50 mg isoflavones/day; genistein to daidzein ratio 2:1)
Trial: 4923928
Drug: Amitriptyline 75
RxNorm normalized name: amitriptyline 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 75 mg/day
Trial: 11717605
Drug: COER verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COER verapamil 180 to 540 mg once daily in the evening for up to 10 weeks
Trial: 11717605
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator agent
Trial: 9553866
Drug: 0.1% ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% ketorolac tromethamine oral rinse, twice daily for 6 months
Trial: 7894000
Drug: Intravenous alfacalcidol
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alfacalcidol (4 micrograms, thrice-weekly for 6 weeks)
Trial: 7894000
Drug: Oral alfacalcidol
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral alfacalcidol (4 micrograms, thrice-weekly for 6 weeks)
Trial: 18259100
Drug: Intravenous alfacalcidol
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alfacalcidol
Trial: 7894000
Drug: Oral alfacalcidol
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral alfacalcidol
Trial: 26513991
Drug: Chinese traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese traditional treatment after routine treatment
Trial: 23884027
Drug: Mud-bath therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud-bath therapy (MBT) for more than 10 years (group A)
Trial: 23884027
Drug: Mud-bath therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud-bath therapy (MBT) for 3 to 10 years (group B)
Trial: 19240655
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) - 17beta‐estradiol (1 mg) with cyclic micronized progesterone (200 mg) for 10 days per month
Trial: 9403359
Drug: Methylsergide and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylsergide and Propranolol (antagonists at 5-HT receptors)
Trial: 9403359
Drug: Ergotamine and
RxNorm normalized name: Belladonna alkaloid and ergotamine and phenobarbital only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergotamine and Sumatriptan (5-HT1 agonists)
Trial: 28855225
Drug: High fiber
RxNorm normalized name: High Fiber Gummies Soft Chew
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fiber from supplement (HFS)
Trial: 23019940
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard chemotherapy)
Trial: 15144931
Drug: Carvedilol (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (maximum dose of 25 mg bid)
Trial: 1642222
Drug: Ranitidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine plus enteric‐coated charcoal (four tablets daily)
Trial: 1642222
Drug: Ranitidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine plus bismuth (30 ml Pepto‐Bismol four times daily)
Trial: 1642222
Drug: Ranitidine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine alone (300 mg at bedtime)
Trial: 1642222
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg at bedtime) with all regimens
Trial: 6800389
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg orally)
Trial: 6138315
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg orally)
Trial: 26012788
Drug: Interferential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential therapy (effective stimulation)
Trial: 21206386
Drug: GEMOX (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEMOX (gemcitabine 1,000 mg/m on days 1 and 8 followed by oxaliplatin 130 mg/m on day 1 every 3 weeks)
Trial: 21206386
Drug: PCb (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCb (paclitaxel 225 mg/m followed by carboplatin AUC = 6 on day 1 every 3 weeks)
Trial: 17466657
Drug: Paroxetine controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine controlled release (12.5-62.5 mg/day)
Trial: 15039515
Drug: Acetylcarnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcarnitine (2 g/d)
Trial: 15039515
Drug: Propionylcarnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionylcarnitine (2 g/d)
Trial: 11478511
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg daily (group A)
Trial: 3479525
Drug: Lecithin treatment
RxNorm normalized name: Lecithin
DrugBank: Lecithin (DB15834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecithin treatment
Trial: 9683394
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil treatment
Trial: 7849232
Drug: Cefoperazone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone (1 g administered intravenously over 3-5 min)
Trial: 3154472
Drug: T-cell antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-cell antibody positive cases
Trial: 23631804
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplement (50,000 IU weekly for 8 weeks and 50,000 IU monthly for 10 months)
Trial: 22151921
Drug: Gluteal intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluteal intramuscular corticosteroid injection
Trial: 22151921
Drug: Gluteal intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluteal intramuscular placebo (saline) injection
Trial: 19673352
Drug: Cefteram pivoxil
RxNorm normalized name: cefteram pivoxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefteram pivoxil (CFTM‐PI) 300 mg, three times daily for three days (Group B)
Trial: 19673352
Drug: Cefteram pivoxil
RxNorm normalized name: cefteram pivoxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefteram pivoxil (CFTM‐PI) 300 mg, three times daily for five days (Group C)
Trial: 19673352
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral antimicrobial administration (Group A)
Trial: 10776974
Drug: Tiorfan (racecadotril)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiorfan (racecadotril) 300 mg/day from D0 to D15
Trial: 10776974
Drug: Tiorfan (racecadotril)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiorfan (racecadotril) 300 mg/day
Trial: 31356535
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) 0.5-µg/kg overload dose for 10 minutes and a 0.5-μg/kg/h maintenance dose
Trial: 22281837
Drug: Virtual coach
RxNorm normalized name: coachwhip stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual coach intervention (automated, animated computer agent providing personalized feedback and goal setting)
Trial: 1983344
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg q.d.s. for 1 week
Trial: 1983344
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg nocte for 1 week
Trial: 1983344
Drug: Sufotidine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufotidine 300 mg b.d. for 1 week